Methods for treatment of ocular diseases
Inventors
Foster, Timothy Paul • Rodriguez, Paulo Cesar • Hill, James Milton • Ochoa, Augusto
Assignees
National Institutes of Health NIH • Louisiana State University • US Department of Health and Human Services
Publication Number
US-8877183-B2
Publication Date
2014-11-04
Expiration Date
2033-03-14
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Methods and therapeutic treatments of ocular diseases are provided including applying peg-Arginase I to affected eyes. Methods are provided that simultaneously treat inflammation and neovascularization of eyes while promoting healing. Methods are provided to treat lesions or infections of an eye.
Core Innovation
The invention provides methods and therapeutic treatments for ocular diseases by applying peg-Arginase I to affected eyes. This application simultaneously treats inflammation and neovascularization of the eyes while promoting healing. It targets the corneal tissue and is effective against infections, trauma, and inflammation-mediated ocular diseases.
The problem addressed is that ocular trauma, infection, or surgery can initiate inflammatory reactions and neovascularization, leading to corneal thickening, opacification, reduced visual clarity, or blindness. Existing treatments like corticosteroids reduce inflammation but have severe side effects such as increased infection risk, delayed healing, and deterioration of vision. There is a lack of treatments that can effectively control pathogen replication, inflammation, and neovascularization simultaneously without these side effects.
Claims Coverage
The patent includes several independent claims that outline inventive features related to the application of peg-Arginase I to infected or affected eyes, focusing on treating drug resistant infections, inflammation, neovascularization, and promoting healing.
Use of peg-Arginase I for treating eyes infected with drug resistant infectious agents
A method comprising exogenous application of peg-Arginase I to an eye infected by a drug resistant infectious agent which simultaneously inhibits inflammation and neovascularization of corneal tissue and promotes healing.
Peg-Arginase I ophthalmic formulation for treating ocular diseases caused by drug resistant agents
A therapeutic method applying a peg-Arginase I containing ophthalmic formulation to an affected eye with ocular disease caused by infection with a drug resistant infectious agent, where the affected eye presents with inflammation and/or neovascularization.
Ocular antiviral treatment using peg-Arginase I against drug resistant viruses
Application of peg-Arginase I in an ophthalmic formulation to an eye infected by a drug resistant virus, inhibiting viral replication including viruses such as HSV-1, HSV-2, CMV, VZV, and Adenovirus.
Prevention of ocular neovascularization using peg-Arginase I
Applying peg-Arginase I ophthalmic formulation, comprising peg-Arginase I and free peg molecules, to an affected eye infected by a drug resistant infectious agent to prevent neovascularization.
Prevention of ocular inflammation using peg-Arginase I
Applying peg-Arginase I ophthalmic formulation, comprising peg-Arginase I and free peg molecules, to an affected eye infected by a drug resistant infectious agent to prevent inflammation.
The claims collectively cover methods applying peg-Arginase I to treat and prevent inflammation, neovascularization, and infection including drug resistant agents in mammalian eyes, employing peg-Arginase I ophthalmic formulations with free PEG molecules and pH buffers.
Stated Advantages
Simultaneously treats inflammation and neovascularization while promoting corneal healing.
Effective against a broad spectrum of pathogens including drug resistant viruses and bacteria.
Targets pathways unlikely to lead to drug resistance development.
Prevents vision-threatening corneal neovascularization and edema.
Reduces or eliminates ocular inflammatory discharge without increasing infection risk.
Exhibits improved clinical outcomes compared to existing antivirals and corticosteroids, with fewer side effects.
Documented Applications
Treatment of ocular diseases caused by pathogenic infections including HSV-1, HSV-2, CMV, VZV, Adenovirus, and drug resistant strains thereof.
Treatment of corneal trauma from accidental injury, surgical procedures, mechanical impacts, or pathogenic infection.
Treatment and prevention of ocular inflammation and neovascularization associated with various ocular diseases.
Treatment of ocular lesions and infections to accelerate corneal wound healing while reducing inflammation and neovascularization.
Veterinary applications including diseases affecting feline, canine, and equine eyes.
Interested in licensing this patent?